Belgium· BE-AMP-SAM521484-00
MabThera 1600 mg
A rituximab product containing rituximab, registered in Belgium by Roche Registration. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Rituximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FA01 (rituximab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Rituximab · ATC L01FA01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rituximab costs, country by country.
Normalised to the WHO defined daily dose (67 mg), the median price runs from $3.15 in Finland to $96.14 in Switzerland — a ×31 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rituximab · price per daily dose (67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$96.14
- FI Finland$3.15
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Rituximab
- Manufacturer
- Roche Registration
- Country
- Belgium (BE)
- ATC code
- L01FA01
- ATC class
- Rituximab
- Defined daily dose
- 67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7722135
- be_apb3466471
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for rituximab.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rituximab · interactions on record
81 records
- 32 severe
- 42 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rituximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMABTHERARoche Registration GmbH, Grenzach-Wyhlen
- IcelandMabTheraRoche Registration GmbH*
- NorwayMabTheraRoche Registration GmbH
- SwedenMabThera 1600 mg Injektionsvätska, lösningRoche Registration GmbH
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e280094-9484-4cd3-b100-919e4160d25a GET /v1/drugs/2e280094-9484-4cd3-b100-919e4160d25a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "MabThera 1600 mg",
"name_fr": "MabThera 1600 mg",
"name_nl": "MabThera 1600 mg",
"amp_code": "SAM521484-00",
"strengths": [
"120.0000",
"1.0000"
],
"pack_count": 1,
"substances": [
"Rituximab",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Rituximab",
"authorisation_numbers": [
"EU/1/98/067/004"
]
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.